Nouscom Appoints Adrian Woolfson as CMO

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).

ADVERTISEMENT

At Nouscom Dr. Woolfson will play a key role in leading the Company’s clinical development of its neoantigen off-the-shelf vaccine targeting tumors associated with Microsatellite Instability (MSI), as well as the personalized neoantigen vaccines and oncolytic virus programs.

“We are pleased to welcome Adrian, a seasoned pharmaceutical industry executive with highly relevant immunotherapy experience, to Nouscom’s management team,” said Alfredo Nicosia, Chief Executive Officer of Nouscom. “Adrian’s extensive immunotherapy drug development experience will allow us to leverage the clinical potential of our best-in-class platform as we look to enter our lead program, NOUS-209, an off-the-shelf cancer vaccine, into the clinic.”

Dr. Woolfson joins Nouscom from Pfizer where he most recently served as Global Clinical Leader Early and Late Stage Immuno-Oncology/Hematology and was responsible for building a diverse portfolio of monotherapy and combination studies for Pfizer’s PD-L1 inhibitor Bavencio and 4-1BB agonist Utomilumab. Prior to Pfizer, he was Global Clinical Lead at Bristol-Myers Squibb.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!